Trials / Completed
CompletedNCT04800172
The Possible Effects of Roflumilast on Obesity Related Disorders
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism, insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast | administration of roflumilast 500 mcg tablet once daily for 3 months. |
| DRUG | placebo | administration of placebo tablet once daily for 3 months. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2021-03-16
- Last updated
- 2022-04-05
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04800172. Inclusion in this directory is not an endorsement.